<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202512</url>
  </required_header>
  <id_info>
    <org_study_id>1333.43</org_study_id>
    <secondary_id>2014-000320-20</secondary_id>
    <nct_id>NCT02202512</nct_id>
  </id_info>
  <brief_title>Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers</brief_title>
  <official_title>Effect of Repeated Oral Doses of BI 1060469, BI 1021958 and Active Controls, Cimetidine and Naproxen, on Measured GFR Via Renal Clearance of Iohexol in Healthy Male Subjects (a Phase I Study; Single-blind, Randomized, Placebo-controlled Within BI Groups and Open-label for the Active Controls)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Main objective is to investigate the measured glomerular filtration rate (mGFR) as assessed
      by iohexol clearance in healthy male normovolemic subjects after oral administration of
      single and repeated doses of BI 1060469, and BI 1021958.

      The secondary objective of this trial is to investigate the glomerular filtration rate (GFR)
      as assessed by 24 hours creatinine clearance in healthy male normovolemic subjects after oral
      administration of single and repeated doses of BI 1060469, and BI 1021958.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measured glomerular filtration rate (mGFR) based on renal iohexol clearance</measure>
    <time_frame>up to day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>measured urinary 24-hour creatinine clearance</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1060469 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose,Tablet,oral administration with 240 ml water,over 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1060469 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose,Tablets,oral administration with 240 ml water, over 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cimetidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose,Tablets,oral administration with 240 ml water, over 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine</intervention_name>
    <arm_group_label>Cimetidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1021958</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1060469 high dose</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1060469 low dose</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1021958</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1021958</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects according to the investigators assessment, as based on the
             following criteria: a complete medical history including a physical examination, vital
             signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and
             clinical laboratory tests, including negative test result on occult blood in stool
             (only for subjects assigned to Naproxen)

          -  Age 18 to 45 years (incl.)

          -  Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with good clinical practice (GCP) and local legislation

        Exclusion criteria:

          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal
             and judged clinically relevant by the investigator

          -  Repeated measurement of systolic blood pressure greater than 140 mm Hg, diastolic
             blood pressure greater than 90 mm Hg, or pulse rate outside the range of 50 to 90 mmHg

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Serum creatinine laboratory value out of the normal range

          -  GFR (Glomerular Filtration Rate) &lt; 90 mL/ min at screening

          -  Urinary toral protein/creatinine ratio &gt; 0,1 mg protein/ mg creatinine

          -  Current or history of relevant kidney, urinary tract diseases or abnormalities (i.e.
             nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal
             failure, infections)

          -  Further exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1333.43.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

